BioMarin Pharmaceutical Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$86.8M
Doctors Paid
4,282
Transactions
24,196
2024 Total
$11.6M
Payment Breakdown by Category
Research$69.0M (79.5%)
Consulting$2.0M (2.3%)
Travel$1.6M (1.8%)
Food & Beverage$470,518 (0.5%)
Royalty/License$164,100 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $69.0M | 8,144 | 79.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11.8M | 2,437 | 13.7% |
| Consulting Fee | $2.0M | 539 | 2.3% |
| Travel and Lodging | $1.6M | 3,040 | 1.8% |
| Education | $1.1M | 1,354 | 1.2% |
| Grant | $528,977 | 49 | 0.6% |
| Food and Beverage | $470,518 | 8,593 | 0.5% |
| Royalty or License | $164,100 | 4 | 0.2% |
| Charitable Contribution | $157,000 | 6 | 0.2% |
| Honoraria | $45,167 | 21 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $23,102 | 1 | 0.0% |
| Gift | $1,726 | 8 | 0.0% |
Payments by Type
Research
$69.0M
8,144 transactions
General
$17.8M
16,052 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Phase 3 substudy enrolling approximately 100 subjects aged 18 to 70 years old with PKU who are concurrently participating in the 165-302 study | $5.6M | 0 | 420 |
| Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients | $5.6M | 0 | 662 |
| Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU Prism302 | $4.2M | 0 | 367 |
| Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU Prism302) | $3.9M | 0 | 330 |
| An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia | $3.7M | 0 | 387 |
| PKU Demographics, Outcomes, and Safety Registry | $3.3M | 0 | 800 |
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia | $3.1M | 2 | 320 |
| A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondroplasia | $2.9M | 0 | 294 |
| Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU (Prism302) | $2.6M | 0 | 194 |
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children with Achondroplasia, Age 0 to < 60 Months | $2.0M | 0 | 145 |
| Multicenter multinational study to collect consistent baseline growth measurements on pediatric patients with Achondroplasia being considered for subsequent enrollment in Study 111-202. No study drug is administered. | $1.6M | 0 | 302 |
| A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease | $1.5M | 0 | 33 |
| A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia | $1.4M | 0 | 263 |
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children with Achondroplasia, Age 0 to 60 Months | $1.3M | 2 | 125 |
| A Phase 2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients 18 Years of Age With CLN2 Disease | $1.1M | 1 | 15 |
| Multi-Center achondroplasia patient registry | $1.1M | 0 | 7 |
| A Prospective Non-Interventional Study of Bleeding Episodes, Factor VIII Infusions, and Patient-Reported Outcomes in Individuals with Severe Hemophilia A | $932,268 | 0 | 218 |
| An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase 40 mgday Dose) in Adults with Phenylketonuria | $922,256 | 0 | 187 |
| An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/day Dose) in Adults with Phenylketonuria | $894,945 | 0 | 198 |
| Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU PAL-003 | $803,184 | 0 | 97 |
| A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Intracerebroventricular BMN 250 in Patients with Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B) | $768,910 | 0 | 12 |
| Multicenter multinational study to collect consistent baseline growth measurements on pediatric patients with Achondroplasia being considered for subsequent enrollment in Study 111-202 No study drug is administered | $757,923 | 0 | 152 |
| Morquio A Registry Study MARS) | $751,674 | 1 | 227 |
| Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003) | $693,967 | 0 | 71 |
| A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease | $642,684 | 0 | 26 |
| A Phase 2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease | $579,146 | 0 | 14 |
| A Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia | $547,440 | 0 | 40 |
| Morquio A Registry Study (MARS) | $533,629 | 0 | 185 |
| BMN 111-902 | $482,399 | 0 | 46 |
| Achondroplasia Natural History Study multi-center clinical study | $467,992 | 0 | 6 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Barbara Konkle, Md, MD | Hematology & Oncology | Seattle, WA | $38,820 | $0 |
| Spencer Sullivan, Md, MD | Pediatric Hematology-Oncology | Madison, MS | $38,673 | $0 |
| Paul Saenger, Md, MD | Pediatric Endocrinology | Mineola, NY | $38,664 | $0 |
| Miguel Escobar, M.d, M.D | Internal Medicine | Houston, TX | $38,509 | $0 |
| Dr. Ingrid Cristian, Md, MD | Clinical Genetics (M.D.) | Orlando, FL | $38,097 | $0 |
| Mrs. Erika Vucko, Apn, APN | Nurse Practitioner | Chicago, IL | $37,973 | $0 |
| Dr. Nigel Key, Md, MD | Hematology & Oncology | Chapel Hill, NC | $36,593 | $0 |
| Michael Wang, Md, MD | Pediatric Hematology-Oncology | Aurora, CO | $36,552 | $0 |
| Allison Bannick, Np, NP | Pediatrics | Grand Rapids, MI | $36,524 | $0 |
| Dr. Elaine Majerus, Md, MD | Hematology | Saint Louis, MO | $35,928 | $0 |
| Dr. Markey Mcnutt, Md, MD | Endocrinology, Diabetes & Metabolism | Dallas, TX | $35,807 | $0 |
| Kevin Winthrop, Md, MD | Infectious Disease | Portland, OR | $35,213 | $0 |
| Dr. Robert Gensure, Md, MD | Pediatric Endocrinology | Manchester, NH | $34,958 | $0 |
| John Phillips, Md, MD | Pediatrics | Nashville, TN | $34,403 | $0 |
| Dr. Gillian Shepherd, M.d, M.D | Allergy | New York, NY | $34,091 | $0 |
| Kenneth Berger, M.d, M.D | Pulmonary Disease | New York, NY | $33,384 | $0 |
| Dr. Raymond Wang, Md, MD | Pediatrics | Orange, CA | $32,804 | $0 |
| Vivek Sharma, Md, MD | Hematology & Oncology | Louisville, KY | $32,718 | $0 |
| Dr. Randheer Shailam, Md, MD | Diagnostic Radiology | Boston, MA | $32,468 | $0 |
| Vernon Sutton, Md, MD | Clinical Genetics (M.D.) | Houston, TX | $32,063 | $0 |
| Robert Sidonio, Md, MD | Pediatric Hematology-Oncology | Atlanta, GA | $30,661 | $0 |
| Daniel Hoernschemeyer, Md, MD | Pediatric Orthopaedic Surgery | Columbia, MO | $30,480 | $0 |
| Dr. Michael Callaghan, M.d, M.D | Pediatric Hematology-Oncology | Detroit, MI | $29,550 | $0 |
| Dr. Donald Basel, M.b.b.ch, M.B.B.CH | Pediatrics | Milwaukee, WI | $29,282 | $0 |
| Dr. David Dimmock, M.d, M.D | Clinical Genetics (M.D.) | San Diego, CA | $28,365 | $0 |
Ad
Top Products
- Palynziq $14.8M
- BMN 165 $6.3M
Associated Products (19)
- Palynziq $14.8M
- BMN 165 $6.3M
- VOXZOGO 1.2MG $6.2M
- Brineura $5.3M
- Kuvan $4.7M
- BMN 111 $4.5M
- PALYNZIQ $3.6M
- Vimizim $2.2M
- ROCTAVIAN $1.1M
- BMN 270 $981,035
- VOXZOGO 1.2mg $717,945
- BMN 250 $606,047
- Naglazyme $572,823
- Roctavian $402,883
- BRINEURA $267,269
- VIMIZIM $241,345
- BMN 190 $218,035
- VOXZOGO $176,260
- BMN 701 $120,996
Payment Categories
- Food & Beverage $470,518
- Consulting $2.0M
- Travel & Lodging $1.6M
- Research $69.0M
- Royalties $164,100
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. has made $86.8M in payments to 4,282 healthcare providers, recorded across 24,196 transactions in the CMS Open Payments database. In 2024, the company paid $11.6M. The top product by payment volume is Palynziq ($14.8M).
Payments were distributed across 141 medical specialties. The top specialty by payment amount is Hematology & Oncology ($4.3M to 34 doctors).
Payment categories include: Food & Beverage ($470,518), Consulting ($2.0M), Research ($69.0M), Travel & Lodging ($1.6M), Royalties ($164,100).
BioMarin Pharmaceutical Inc. is associated with 19 products in the CMS Open Payments database, including Palynziq, BMN 165, and VOXZOGO 1.2MG.